7,449.50

+47.50

+0.64%

51,767.00

+382.00

+0.74%

27,260.75

+175.50

+0.65%

Russell 2000 Futures

2,784.20

+23.70

+0.86%

4.8590

+0.0220

+0.45%

25.64

-2.54

-9.01%

4,128.60

+53.70

+1.32%

74,911.14

-895.15

-1.18%

Crude Oil Dec 26

91.06

+0.23

+0.25%

US Private Equity

10,772.76

+11.83

+0.11%

OTC Markets OTCQB - Delayed Quote USD

Provectus Biopharmaceuticals, Inc. (PVCT)

0.0530 +0.0010 (+1.92%)

At close: November 6 at 4:00:00 PM EST

Loading Chart for PVCT

Chart Range Bar

Interval:

In partnership with ChartIQ

Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose

Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose

Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections

Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections

Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)

Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)

Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End

Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End

Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis

Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis

Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee

Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee

Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment

Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment

VisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company Showcase

VisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company Showcase

Mobilize your Website

View Site in Mobile | Classic

Share by: